You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALK gene fusion

Showing 1 - 25 of 7,878
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

Withdrawn
  • Advanced Malignant Neoplasm
  • +10 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Trial in Shanghai (SIM1803-1A)

Recruiting
  • Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion
  • Shanghai, China
    Shanghai Chest Hospital
Jan 11, 2021

NUT Midline Carcinoma, Triple Negative Breast Cancer, NSCLC With Rearranged ALK Gene/Fusion Protein or KRAS Mutation Trial

Completed
Has Results
  • NUT Midline Carcinoma
  • +5 more
  • (no location specified)
Jan 7, 2021

NSCLC Stage IV, ALK Fusion Protein Expression Trial (Peptide vaccine)

Not yet recruiting
  • NSCLC Stage IV
  • ALK Fusion Protein Expression
  • Peptide vaccine
  • (no location specified)
Jul 21, 2023

Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life

Recruiting
  • Cancer
  • +15 more
  • Data collection and quality of life questionnaire
  • Graz, Austria
  • +40 more
Jul 27, 2021

NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation Trial in France (Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab,

Recruiting
  • NSCLC Stage IIIB
  • +4 more
  • Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
  • Carboplatin + Pemetrexed + Atezolizumab
  • Angers, France
  • +30 more
Jun 7, 2021

Learn More About NTRK Gene Fusion Positive in Solid Tumor in

Not yet recruiting
  • Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
  • No Drug
  • Multiple Locations, Japan
    Many Locations
Mar 20, 2023

Non Small Cell Lung Cancer, NSCLC, NSCLC Trial in Australia, Korea, Republic of, United States (TPX-0131)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • +5 more
  • Orange, California
  • +13 more
Nov 7, 2022

Patient Journey With Advanced Lung Cancer Positive for ALK

Recruiting
  • Carcinoma, Non-Small-Cell Lung
    • Fortaleza, Ceará, Brazil
    • +4 more
    Sep 26, 2022

    Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer Trial in France (Blood and tumor samples)

    Recruiting
    • Soft Tissue Sarcoma
    • +2 more
    • Blood and tumor samples
    • Clermont-Ferrand, France
    • +9 more
    Dec 8, 2021

    ALK Fusion-positive Solid or CNS Tumors Trial in Worldwide (Alectinib)

    Recruiting
    • ALK Fusion-positive Solid or CNS Tumors
    • New York, New York
    • +17 more
    Jul 25, 2022

    Glioblastoma Trial in Beijing (PLB1001, Temozolomide, Cisplatin combined with Etoposide)

    Active, not recruiting
    • Glioblastoma
    • Beijing, Beijing, China
      Beijing Tiantan Hospital,Capital Medical University
    Oct 27, 2023

    NTRK Gene Fusion - Positive Advanced or Recurrent Solid

    Recruiting
    • Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
    • Larotrectinib (Vitrakvi, BAY2757556)
    • Multiple Locations, Japan
      Many locations
    Jan 20, 2023

    Solid Tumors Trial (afatinib)

    No longer available
    • Solid Tumors
    • (no location specified)
    Nov 7, 2022

    Either EML4-ALK Gene Rearrangements or T790M EGFR Mutation in

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
      • Hollywood, Florida
      • +1 more
      Sep 29, 2021

      ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy Trial in Changsha (Pembrolizumab Combined With Bevacizumab and

      Not yet recruiting
      • ALK Gene Mutation
      • +2 more
      • Pembrolizumab Combined With Bevacizumab and Chemotherapy
      • Changsha, Hunan, China
        Hunan Cancer Hospital
      Jul 14, 2022

      Radiotherapy Side Effect, NSCLC, ALK Gene Mutation Trial in Stockholm (SBRT/SRS/radiation therapy)

      Not yet recruiting
      • Radiotherapy Side Effect
      • +2 more
      • SBRT/SRS/radiation therapy
      • Stockholm, Sweden
        Karolinska University Hospital
      Feb 16, 2023

      NSCLC Stage IIIB, ALK Gene Mutation Trial in Mexico City (Alectinib Oral Product)

      Recruiting
      • Non-small Cell Lung Cancer Stage IIIB
      • ALK Gene Mutation
      • Alectinib Oral Product
      • Mexico City, Mexico
        Thoracic Oncology Unit and Personalized Medicine Laboratory, Ins
      Jan 26, 2023

      PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene

      Recruiting
      • Non Small Cell Lung Cancer
        • Changsha, Hunan, China
          Yongchang Zhang
        Mar 9, 2022

        Helicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit

        Not yet recruiting
        • Helicobacter Pylori Infection
        • +3 more
        • Detection of fecal samples with diagnostic kit
        • +2 more
        • (no location specified)
        Jun 5, 2022

        NSCLC, Stage III, ALK-rearrangement Trial in Worldwide (Brigatinib, Durvalumab)

        Not yet recruiting
        • NSCLC, Stage III
        • ALK-rearrangement
        • Angers, France
        • +19 more
        Feb 8, 2023

        NSCLC, ALK Gene Rearrangement Positive Trial in United States (Ensartinib)

        Available
        • Non-Small Cell Lung Cancer
        • ALK Gene Rearrangement Positive
        • Stanford, California
        • +3 more
        Oct 18, 2022

        NSCLC, Pancreatic Cancer, Locally Advanced Solid Tumor Trial in Sydney (HMBD-001, Docetaxel, Nab-paclitaxel)

        Not yet recruiting
        • Non-Small Cell Lung Cancer
        • +3 more
        • Sydney, New South Wales, Australia
          GenesisCare North Shore
        Jun 16, 2023

        ALK Fusion Protein Expression, Adjuvant Therapy, NSCLC Trial (Ensatinib, chemo)

        Not yet recruiting
        • ALK Fusion Protein Expression
        • +2 more
        • (no location specified)
        Jan 10, 2022

        A Retro-/Prospective, Non-interventional, Cohort Study in Adult

        Active, not recruiting
        • Solid Tumor, Adult
        • +2 more
          • Amiens, France
          • +3 more
          Jul 22, 2022